A mouse model of ALS with the SOD1G93A mutation, treated with EGFR inhibitor erlotinib, showed a delay in symptom progression but their lifespan was not extended and this drug does not seem to be effective in protecting motor synapses [195]. This evidence concerns the gene EGFR and amyotrophic lateral sclerosis.